CTOs on the Move

L7 Informatics

www.l7informatics.com

 
L7 Informatics provides software and services that enable synchronized solutions for science + health. L7`s novel L7|ESP is a scientific process and data management (SPDM) solution that enables life science and healthcare companies to connect people, processes, and systems to accelerate discoveries and drive precision healthcare.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

L7 Informatics raised $13M on 03/08/2021
L7 Informatics raised $38M on 06/07/2022

Similar Companies

Stellar Biotechnologies

Stellar Biotechnologies is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimers, and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

XTL Biopharmaceuticals

XTL Biopharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trevena

Trevena is a publicly traded clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. We have three programs in clinical development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently in phase 2 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in phase 1 testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.

Micell Technologies

Micell Technologies Inc is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.